. Author manuscript; available in PMC: 2012 Oct 19.

Published in final edited form as: J Allergy Clin Immunol. 2007 Sep 29;120(5):1146–1152. doi: 10.1016/j.jaci.2007.07.055

TABLE I.

Model parameters for base-case and sensitivity analysis

Attribute	Baseline assumptions	Range for sensitivity analysis	Sources
Reduction in exacerbation rates (%)	46	33-92	Walker et al²⁵
Reduction in duration/intensity of hospitalizations (%)	63	—	Busse et al,² Corren et al²⁶
Increase in quality of life (%)	0.9	0-7.2	Niebauer et al²⁸
Increase in FEV₁ % predicted (%)	2.9	—	Walker et al²⁵
Monthly cost^* ($)	1300	100-2500	Drug Topics Red Book, 2005²⁷

Monthly cost calculated based on yearly cost of omalizumab in 2005 dollars for a 70-kg adult with an IgE level of 200 IU/mL.